Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Frosty Loechel is active.

Publication


Featured researches published by Frosty Loechel.


Journal of Biological Chemistry | 1998

A NOVEL, SECRETED FORM OF HUMAN ADAM 12 (MELTRIN ALPHA ) PROVOKES MYOGENESIS IN VIVO

Brent J. Gilpin; Frosty Loechel; Marie-Geneviève Mattei; Eva Engvall; Reidar Albrechtsen; Ulla M. Wewer

The ADAM (A DisintegrinAnd Metalloprotease) family of cell-surface proteins may have an important role in cellular interactions and in modulating cellular responses. In this report we describe a novel, secreted form of human ADAM 12 (meltrin α), designated ADAM 12-S (S for short), and a larger, membrane-bound form designated ADAM 12-L (L for long form). These two forms arise by alternative splicing of a single gene located on chromosome 10q26. Northern blotting demonstrated that mRNAs of both forms are abundant in human term placenta and are also present in some tumor cell lines. The ADAM 12-L transcript can also be detected in normal human adult skeletal, cardiac, and smooth muscle. Human A204 embryonal rhabdomyosarcoma cells that do not differentiate into muscle cells and do not express any form of ADAM 12 were stably transfected with an ADAM 12-S minigene encoding the disintegrin domain, the cysteine-rich domain, and the unique 34 amino acid carboxyl terminus. Nude mouse tumors derived from these transfected cells contained ectopic muscle cells of apparent mouse origin as shown by species-specific markers. These results may have potential applications in the development of muscle-directed gene and cell therapies.


American Journal of Pathology | 1999

Cysteine-Rich Domain of Human ADAM 12 (Meltrin α) Supports Tumor Cell Adhesion

Kousuke Iba; Reidar Albrechtsen; Brent J. Gilpin; Frosty Loechel; Ulla M. Wewer

The ADAMs (A disintegrin and metalloprotease) comprise a family of membrane-anchored cell surface proteins with a putative role in cell-cell and/or cell-matrix interactions. By immunostaining, ADAM 12 (meltrin α) was up-regulated in several human carcinomas and could be detected along the tumor cell membranes. Because of this intriguing staining pattern, we investigated whether human ADAM 12 supports tumor cell adhesion. Using an in vitro assay using recombinant polypeptides expressed in Escherichia coli, we examined the ability of individual domains of human ADAM 12 and ADAM 15 to support tumor cell adhesion. We found that the disintegrin-like domain of human ADAM 15 supported adhesion of αvβ3-expressing A375 melanoma cells. In the case of human ADAM 12, however, recombinant polypeptides of the cysteine-rich domain but not the disintegrin-like domain supported cell adhesion of a panel of carcinoma cell lines. On attachment to recombinant polypeptides from the cysteine-rich domain of human ADAM 12, most tumor cell lines, such as MDA-MB-231 breast carcinoma cells, were rounded and associated with numerous actin-containing filopodia and used a cell surface heparan sulfate proteoglycan to attach. Finally, we demonstrated that authentic full-length human ADAM 12 could bind to heparin Sepharose. Together these results suggest a novel role of the cysteine-rich domain of ADAM 12 — that of supporting tumor cell adhesion.


Journal of Clinical Investigation | 1997

Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy.

Pierre H. Vachon; Hong Xu; Ling Liu; Frosty Loechel; Y Hayashi; K Arahata; J C Reed; Ulla M. Wewer; Eva Engvall

Mutations in genes coding for dystrophin, for alpha, beta, gamma, and delta-sarcoglycans, or for the alpha2 chain of the basement membrane component merosin (laminin-2/4) cause various forms of muscular dystrophy. Analyses of integrins showed an abnormal expression and localization of alpha7beta1 isoforms in myofibers of merosin-deficient human patients and mice, but not in dystrophin-deficient or sarcoglycan-deficient humans and animals. It was shown previously that skeletal muscle fibers require merosin for survival and function (Vachon, P.H., F. Loechel, H. Xu, U.M. Wewer, and E. Engvall. 1996. J. Cell Biol. 134:1483-1497). Correction of merosin deficiency in vitro through cell transfection with the merosin alpha2 chain restored the normal localization of alpha7beta1D integrins as well as myotube survival. Overexpression of the apoptosis-suppressing molecule Bcl-2 also promoted the survival of merosin-deficient myotubes, but did not restore a normal expression of alpha7beta1D integrins. Blocking of beta1 integrins in normal myotubes induced apoptosis and severely reduced their survival. These findings (a) identify alpha7beta1D integrins as the de facto receptors for merosin in skeletal muscle; (b) indicate a merosin dependence for the accurate expression and membrane localization of alpha7beta1D integrins in myofibers; (c) provide a molecular basis for the critical role of merosin in myofiber survival; and (d) add new insights to the pathogenesis of neuromuscular disorders.


Journal of Clinical Investigation | 1998

Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models.

Hong Xu; Pierre H. Vachon; Ling Liu; Frosty Loechel; Ulla M. Wewer; Eva Engvall

Humans and mice with deficiency of the alpha2 subunit of the basement membrane protein laminin-2/merosin suffer from merosin-deficient congenital muscular dystrophy (MCMD). We have expressed a human laminin alpha2 chain transgene under the regulation of a muscle-specific creatine kinase promoter in mice with complete or partial deficiency of merosin. The transgene restores the synthesis and localization of merosin in skeletal muscle, and greatly improves muscle morphology and integrity and the health and longevity of the mice. However, the transgenic mice share with the nontransgenic dystrophic mice a progressive lameness of hind legs, suggestive of a nerve defect. These results indicate that the absence of merosin in tissues other than the muscle, such as nervous tissue, is a critical component of MCMD. Future gene therapies of human MCMD, and perhaps of other forms of muscular dystrophy, may require restoration of the defective gene product in multiple tissues.


Journal of Biological Chemistry | 1999

Regulation of Human ADAM 12 Protease by the Prodomain EVIDENCE FOR A FUNCTIONAL CYSTEINE SWITCH

Frosty Loechel; Michael Toft Overgaard; Claus Oxvig; Reidar Albrechtsen; Ulla M. Wewer

The ADAMs (a disintegrinand metalloprotease) are a family of multidomain proteins that are believed to play key roles in cell-cell and cell-matrix interactions. We have shown recently that human ADAM 12-S (meltrin α) is an active metalloprotease. It is synthesized as a zymogen, with the prodomain maintaining the protease in a latent form. We now provide evidence that the latency mechanism of ADAM 12 can be explained by the cysteine switch model, in which coordination of Zn2+ in the active site of the catalytic domain by a cysteine residue in the prodomain is critical for inhibition of the protease. Replacing Cys179 with other amino acids results in an ADAM 12 proform that is proteolytically active, but latency can be restored by placing cysteine at other positions in the propeptide. None of the amino acids adjacent to the crucial cysteine residue is essential for blocking activity of the protease domain. In addition to its latency function, the prodomain is required for exit of ADAM 12 protease from the endoplasmic reticulum. Tissue inhibitor of metalloprotease-1, -2, and -3 were not found to block proteolytic activity of ADAM 12, hence a physiological inhibitor of ADAM 12 protease in the extracellular environment remains to be identified.


American Journal of Pathology | 2002

ADAM 12 protease induces adipogenesis in transgenic mice.

Nobuko Kawaguchi; Xiufeng Xu; Rie Tajima; Pauliina Kronqvist; Christina Sundberg; Frosty Loechel; Reidar Albrechtsen; Ulla M. Wewer

ADAM 12 (meltrin-alpha) is a member of the ADAM (a disintegrin and metalloprotease) family. ADAM 12 functions as an active metalloprotease, supports cell adhesion, and has been implicated in myoblast differentiation and fusion. Human ADAM 12 exists in two forms: the prototype membrane-anchored protein, ADAM 12-L, and a shorter secreted form, ADAM 12-S. Here we report the occurrence of adipocytes in the skeletal muscle of transgenic mice in which overexpression of either form is driven by the muscle creatine kinase promoter. Cells expressing a marker of early adipogenesis were apparent in the perivascular space in muscle tissue of 1- to 2-week-old transgenic mice whereas mature lipid-laden adipocytes were seen at 3 to 4 weeks. Moreover, female transgenics expressing ADAM 12-S exhibited increases in body weight, total body fat mass, abdominal fat mass, and herniation, but were normoglycemic and did not exhibit increased serum insulin, cholesterol, or triglycerides. Male transgenics were slightly overweight and also developed herniation but did not become obese. Transgenic mice expressing a truncated form of ADAM 12-S lacking the prodomain and the metalloprotease domain did not develop this adipogenic phenotype, suggesting a requirement for ADAM 12 protease activity. This is the first in vivo demonstration that an ADAM protease is involved in adipogenesis.


FEBS Letters | 1997

Tissue-specific expression of the human laminin α5-chain, and mapping of the gene to human chromosome 20q13.2-13.3 and to distal mouse chromosome 2 near the locus for the ragged (Ra) mutation

Marian E. Durkin; Frosty Loechel; Marie-Geneviève Mattei; Brent J. Gilpin; Reidar Albrechtsen; Ulla M. Wewer

To investigate the function of the laminin α5‐chain, previously identified in mice, cDNA clones encoding the 953‐amino‐acid carboxy terminal G‐domain of the human laminin α5‐chain were characterized. Northern blot analysis showed that the laminin α5‐chain is expressed in human placenta, heart, lung, skeletal muscle, kidney, and pancreas. The human laminin α5‐chain gene (LAMA5) was assigned to chromosome 20q13.2‐q13.3 by in situ hybridization, and the mouse gene (Lama5) was mapped by linkage analysis to a syntonic region of distal chromosome 2, close to the locus for the ragged (Ra) mutation.


Journal of Biological Chemistry | 1996

Structural Organization of the Human and Mouse Laminin β2 Chain Genes, and Alternative Splicing at the 5′ End of the Human Transcript

Marian E. Durkin; Medha Gautam; Frosty Loechel; Joshua R. Sanes; John P. Merlie; Reidar Albrechtsen; Ulla M. Wewer

We have determined the structural organization of the human and mouse genes that encode the laminin β2 chain (s-laminin), an essential component of the basement membranes of the neuromuscular synapse and the kidney glomerulus. The human and mouse genes have a nearly identical exon-intron organization and are the smallest laminin chain genes characterized to date, due to the unusually small size of their introns. The laminin β2 chain genes of both species consist of 33 exons that span ≤12 kilobase pairs of genomic DNA. The exon-intron pattern of the laminin β2 chain gene is also highly similar to that of the human genes encoding the homologous laminin β1 and β3 chains. The putative promoter regions of the human and mouse laminin β2 chain genes have features characteristic of the promoters of genes that have a limited tissue expression. Considerable conservation of the intron sequences of the mouse and human genes was observed. The first intron of the human gene, located 1 base pair upstream of the translation start codon, contains a non-consensus 5′ splice site. This intron was shown to be inefficiently spliced in humans, suggesting that post-transcriptional mechanisms may be involved in the regulation of laminin β2 chain gene expression.


FEBS Letters | 2001

Activation of ADAM 12 protease by copper

Frosty Loechel; Ulla M. Wewer

Conversion of latent proteases to the active form occurs by various mechanisms characteristic for different protease families. Here we report that the disintegrin metalloprotease ADAM 12‐S is activated by Cu(II). Copper activation is distinct from the cysteine switch component of latency: elimination of the ADAM 12 cysteine switch by a point mutation in the propeptide had no effect on copper activation, whereas mutation of an unpaired cysteine residue in the catalytic domain resulted in a mutant form of ADAM 12‐S that was insensitive to copper. This suggests a multi‐step activation mechanism for ADAM 12 involving both furin cleavage and copper binding.


Biochemical and Biophysical Research Communications | 2000

ADAM 12-S Cleaves IGFBP-3 and IGFBP-5 and Is Inhibited by TIMP-3☆

Frosty Loechel; Jay W. Fox; Gillian Murphy; Reidar Albrechtsen; Ulla M. Wewer

Collaboration


Dive into the Frosty Loechel's collaboration.

Top Co-Authors

Avatar

Ulla M. Wewer

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rie Tajima

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar

Xiufeng Xu

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar

Eva Engvall

Sanford-Burnham Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eva Engvall

Sanford-Burnham Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar

Finn Cilius Nielsen

Copenhagen University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge